DfuseRx Platform
Solid Tumors (Platform Technology)
PreclinicalDiscovery
Key Facts
Indication
Solid Tumors (Platform Technology)
Phase
Preclinical
Status
Discovery
Company
About Intensity Therapeutics
Intensity Therapeutics is pioneering a 'treat locally, act globally' approach to cancer therapy. Its core DfuseRx platform uses novel penetration enhancers to disperse cytotoxic drugs throughout injected tumors, inducing immunogenic cell death and triggering a CD4+/CD8+ T-cell response against both local and distant metastases. The company is advancing its lead asset, INT230-6, through multiple mid-to-late-stage trials in challenging solid tumors, with a strategic focus on neoadjuvant and metastatic settings to improve survival and prevent recurrence.
View full company profile